Thomas Renaud

Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).

Carolina Schinke, Cyrille Touzeau, Monique C. Minnema et al. · Journal of Clinical Oncology · 2023 · 84 citations

Clinical Immunology, Immunodeficiencies, Immunology +24

Economic vulnerability and unmet healthcare needs among the population aged 50 + years during the COVID-19 pandemic in Europe

Louis Arnault, Florence Jusot, Thomas Renaud · European Journal of Ageing · 2021 · 74 citations · Full text

Health Economics, Economic Vulnerability, Global Health +9

HOW WELL DO DIAGNOSIS‐RELATED GROUPS EXPLAIN VARIATIONS IN COSTS OR LENGTH OF STAY AMONG PATIENTS AND ACROSS HOSPITALS? METHODS FOR ANALYSING ROUTINE PATIENT DATA

Andrew Street, Conrad Kobel, Thomas Renaud et al. · Health Economics · 2012 · 64 citations

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

Ajai Chari, Cyrille Touzeau, Carolina Schinke et al. · The Lancet Haematology · 2025 · 51 citations · Full text

Hematological Malignancy, Medicine, Hematology +7

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Andrzej Jakubowiak, Sébastien Anguille, Lionel Karlin et al. · Blood · 2023 · 43 citations